Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interneuron Pharmaceuticals

Executive Summary

Lexington, Mass.-based startup acquires U.S. marketing rights to prescription anti-obesity drug D-fenfluramine from France's Les Laboratories Servier. Interneuron plans to submit an IND for the serotonin release reuptake inhibitor in "late 1990" as a treatment to suppress carbohydrate craving that can be associated with obesity. Servier currently markets the product in France as an appetite suppressant under the brandname Isomeride. The drug is approved in 30 countries. The neurological R&D firm, which holds licenses for compounds from MIT, was started in 1988 and completed its initial public offering in March.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel